Congress Is Exploring Whether Medicare Can Incentivize Domestic Drug Manufacturing

Pharmaceutical manufacturing has traditionally been influenced by trade policy, tax incentives, and government investment. A new bipartisan Senate proposal suggests Congress is considering another lever: whether Medicare reimbursement could help encourage domestic drug manufacturing.

Legislation introduced by Sens. Adam Schiff, Democrat of California, and Rick Scott, Republican of Florida, would direct the Centers for Medicare and Medicaid Services to examine how its drug coverage and reimbursement authorities could reduce U.S. reliance on foreign pharmaceutical manufacturers. CMS would report its findings to Congress and could recommend reimbursement approaches that support domestic production of active pharmaceutical ingredients, key starting materials, and other critical pharmaceutical inputs.

The bill does not change Medicare payment policy. Instead, it asks whether Medicare's purchasing power could become part of a broader strategy to strengthen the pharmaceutical supply chain.

That question is significant.

For decades, manufacturing policy has largely been shaped through trade measures, grants, and tax incentives. This proposal introduces the possibility that healthcare reimbursement could also influence where pharmaceutical products are manufactured. If reimbursement eventually recognizes domestic production or supply chain resilience, manufacturing decisions could carry implications beyond cost and operational efficiency.

The proposal also reflects a broader policy trend. Governments are increasingly treating pharmaceutical manufacturing as strategic infrastructure rather than simply a commercial activity. The European Union's Critical Medicines Act pursues similar objectives through different policy mechanisms, highlighting a growing international focus on supply chain resilience.

Whether or not this legislation advances, it reflects a broader shift in policymaking. Manufacturing strategy is no longer being shaped solely by operations, trade, and tax policy. Congress is beginning to explore whether healthcare reimbursement should become part of that equation as well.

For pharmaceutical companies, the legislation is less important than the question it asks. If reimbursement policy eventually becomes another tool for strengthening domestic manufacturing, market strategy, capital planning, and manufacturing decisions may become more closely connected than they have been in the past.

At Lanton Strategies International, these are the kinds of intersections we focus on: where reimbursement, trade policy, industrial strategy, and commercial decision making begin to shape one another.

LSI Insight: This article reflects the independent analysis of Lanton Strategies International regarding emerging policy developments and their potential implications for healthcare, life sciences, and health technology organizations. It is intended for informational purposes only and should not be construed as legal, regulatory, or policy advice.

Generic Drug Tariffs Are Not Yet Policy. Companies Still Need a Plan

President Trump has announced that imported generic drugs would remain subject to a zero tariff for two years beginning August 1, 2026. The tariff would then rise to 100% for one year and 200% thereafter. The stated objective is to encourage more pharmaceutical manufacturing in the United States.

The announcement has generated immediate concern about drug prices, shortages, and the exposure of manufacturers that rely heavily on production outside the United States.

There is an important distinction, however, between a policy announcement and an enforceable tariff.

As of July 23, 2026, no new executive order, presidential proclamation, Federal Register notice, Customs and Border Protection guidance, or amendment to the Harmonized Tariff Schedule has been issued to implement the announced generic-drug tariffs.

The existing legal position still says the opposite. The pharmaceutical tariff proclamation issued in April expressly provides that generic pharmaceuticals, biosimilars, and their associated ingredients are not subject to Section 232 tariffs “at this time.” It directs the Secretary of Commerce to continue monitoring generic imports and report within one year on whether additional action may be appropriate.

The announced tariff schedule should therefore be treated as a serious business signal, not as an operative legal obligation.

The Details Will Determine the Real Exposure

Any implementing action would need to answer questions that could materially change its commercial effect.

Would the tariffs apply only to finished generic drugs, or also to active pharmaceutical ingredients and key starting materials? Would biosimilars remain within the generic category? How would the government determine a product’s country of origin when different manufacturing stages occur in different jurisdictions?

It is also unclear whether manufacturers could qualify for lower rates by building or expanding U.S. production. The existing branded-pharmaceutical tariff framework provides different treatment for certain companies with approved onshoring plans, pricing agreements, or operations in countries covered by trade arrangements. Companies should not assume that the same structure will automatically be extended to generics.

Until those details are established, manufacturers cannot calculate their potential tariff liability. Distributors, pharmacies, health plans, and healthcare providers also cannot determine how additional costs might move through the supply chain.

Generic-Drug Economics Make the Risk Different

Generic drugs frequently operate under narrow margins, competitive purchasing contracts, and reimbursement structures that may not adjust quickly when acquisition costs rise.

A manufacturer may not be able to absorb a substantial tariff. It may also lack the contractual ability to pass the full cost to a wholesaler or customer.

For some products, the response may not simply be a higher price. Manufacturers could reconsider whether it remains economically viable to continue supplying a particular drug to the U.S. market.

That creates a potential availability risk, especially for low-margin products, drugs with few suppliers, and medicines already vulnerable to shortage.

Reshoring could strengthen pharmaceutical supply chains over time. Tariffs alone, however, do not resolve the capital, workforce, regulatory, contracting, reimbursement, and purchasing challenges that determine whether domestic generic manufacturing is commercially sustainable.

What Companies Should Do Now

Companies should not treat the announced rates as settled policy or make definitive customs conclusions before formal implementation documents are issued. They should, however, begin evaluating their potential exposure now.

Generic manufacturers and importers can begin mapping products by manufacturing location, ingredient source, country of origin, margin, tariff classification, and contractual ability to pass through higher costs.

Distributors, pharmacies, health plans, and health systems should identify products for which a tariff could create the greatest cost or availability risk.

Investors should evaluate which companies possess credible domestic manufacturing options and which remain dependent on policy exemptions or continued access to lower-cost foreign production.

Leaders should also model several possible outcomes, including:

• Continued exemption for generic drugs

• Tariffs limited to selected products, ingredients, or countries

• Reduced rates for companies making approved U.S. manufacturing commitments

• Broader tariffs covering both finished products and pharmaceutical ingredients

Each scenario could produce different decisions involving sourcing, inventory, contracts, capital investment, pricing, and continued participation in the U.S. market.

The tariff is not yet policy. The strategic question is whether companies will understand their exposure before it becomes one.

Lanton Strategies International advises healthcare, life-sciences, and investment organizations on how trade policy, regulation, reimbursement, market access, and capital developments affect business strategy and commercial execution across the United States, European Union, and United Kingdom.

The New Risk Map for Pharmaceutical Pricing

I was grateful to join Melanie Whittington, PhD on Perspectives by the Leerink Center for Pharmacoeconomics for a conversation about the U.S. Trade Representative’s Section 301 investigation into Germany’s pharmaceutical pricing and reimbursement practices. The interview can be found here.

The investigation itself is important, but I think the larger point is even more important.

The status quo is over.

Pharmaceutical companies and investors can no longer look at pricing, reimbursement, trade policy, launch planning, manufacturing, and patient access as separate issues. These areas are beginning to move together, especially for companies operating across the U.S., EU, and UK.

For a long time, pharmaceutical pricing was mostly treated as a domestic reimbursement issue. In the United States, that meant looking at Medicare, CMS, PBMs, commercial payers, the Inflation Reduction Act, and state-level access questions. In Europe, it meant looking country by country at health technology assessment, national budgets, reimbursement decisions, and launch sequencing.

Those issues still matter. They always will. The difference now is that trade policy is becoming part of the pricing conversation.

Section 301, Section 232, Most Favored Nation-style proposals, tariff discussions, and cross-border pricing arrangements are forcing companies to think differently about market strategy. A pricing decision in one country may no longer stay in that country. A reimbursement proposal in Europe may become part of a broader U.S. trade discussion. A launch strategy that once looked commercially sound may need to be reconsidered through a geopolitical and policy lens.

That is especially important because the EU is not a monolith. The European Union may operate as a commercial bloc in certain contexts, but pharmaceutical pricing and reimbursement remain deeply national. Germany, France, Italy, Spain, the Netherlands, and other countries each bring their own budget pressures, political expectations, health system priorities, and views of value.

That is why it is too simple to say that Europe is just about “price controls.” Pricing decisions are tied to clinical value, budget impact, insurance systems, patient access, politics, and long-term health system planning. Once trade policy enters that discussion, the risk map changes.

This matters for executives, boards, and investors. A company may have strong science, promising clinical data, and a compelling patient story. Those things are essential, but they are no longer enough on their own.

The company also has to explain where it will launch, how it expects to be reimbursed, what pricing assumptions support the business model, how those assumptions could change, and whether trade or policy pressure could affect the commercial plan. These questions matter even for biotech companies that are years away from commercialization because many of the assumptions about market size, pricing, access, manufacturing, and return on investment are made long before launch.

The patient access question cannot be separated from this either. If pricing and trade disputes create uncertainty, companies may delay launches, rethink markets, or narrow their commercial strategy. That can affect whether patients get access to innovative therapies, when they get access, and where that access happens first.

At the same time, policymakers are under pressure to make medicines more affordable and health systems more sustainable. That pressure is not going away.

That is why the next phase of pharmaceutical strategy requires a more connected view. Drug pricing is not only a reimbursement issue. Trade policy is not only a government relations issue. Market access is not only a commercial issue. Investor risk is not only a finance issue.

These issues now move together.

At Lanton Strategies International, we are watching these developments because they sit at the intersection of policy, reimbursement, trade, market access, and capital strategy across the U.S., EU, and UK.

For pharmaceutical companies, biotech executives, investors, and health-sector leaders, the question is not whether the rules are changing.

They are.

The work now is understanding what comes next.

Germany’s Drug Pricing Dispute Now Has a Comment Deadline. Stakeholders Should Pay Attention.

Germany’s pharmaceutical pricing and reimbursement system has moved into a new arena.

In June 2026, the Office of the United States Trade Representative launched a Section 301 investigation titled “Germany’s Persistent Underpayment for Innovative Pharmaceutical Products.” The investigation focuses on whether Germany’s pharmaceutical pricing and reimbursement practices may be unreasonable, discriminatory, or burdensome to U.S. commerce.

The USTR comment docket opened on June 25, 2026. Written comments are due by August 10, 2026, at 11:59 PM EDT.

For German companies, investors, trade associations, and policymakers, this should not be viewed as a routine U.S. trade development.

It is a signal that drug pricing is becoming part of international economic policy.

For many years, pharmaceutical pricing was treated primarily as a domestic healthcare issue. Germany had its system. The United Kingdom had its system. France, the Netherlands, Italy, Spain, and other countries had their own reimbursement frameworks.

Companies still had to understand each market on its own terms. Germany was different from the UK. France was different from the Netherlands. Pricing and reimbursement strategy had to account for those differences, but the debate usually stayed inside the healthcare policy framework.

That is starting to change.

The U.S. government is now using a trade law mechanism to scrutinize how another advanced economy pays for innovative medicines. That does not mean the United States will automatically prevail. It also does not mean Germany will suddenly redesign its statutory health insurance system around U.S. objections.

It does mean the policy risk has changed.

Germany matters because it is one of Europe’s most important pharmaceutical markets. Decisions made in Germany can affect launch sequencing, reference pricing, investor assumptions, and commercial planning across multiple markets.

The U.S. argument appears to be that American patients and the U.S. market are carrying too much of the global cost of pharmaceutical innovation while other wealthy countries use reimbursement systems to pay less.

German and European policymakers are likely to see the issue very differently. From their perspective, pharmaceutical reimbursement is part of national healthcare policy, public budgeting, and statutory insurance design.

That tension is exactly why this investigation matters.

For German life sciences companies and investors, the issue is not only whether this ends with tariffs, negotiations, or no immediate action.

The more important point is that pharmaceutical pricing is being pulled into a wider conversation about trade, investment, reimbursement, and market access.

That has practical consequences. A German pricing decision may no longer stay inside Germany. It can affect launch strategy, investor assumptions, reference pricing, and how policymakers in Washington view the balance between innovation, access, and cost.

The USTR comment period gives stakeholders an opportunity to shape the record. A strong submission should not simply defend or criticize German pricing policy. It should explain the commercial, legal, reimbursement, innovation, and patient-access consequences in a way that U.S. trade policymakers can understand.

At Lanton Strategies International, we help companies, investors, and associations understand how policy developments across the U.S., EU, and UK affect market strategy, pricing risk, reimbursement positioning, and capital planning.

For stakeholders considering whether to submit comments, we can help assess the USTR investigation, develop comment strategy, identify the business and policy issues that should be raised, and translate German reimbursement concerns into the language of U.S. trade policy.

The Germany Section 301 investigation is one of those moments where healthcare policy, trade policy, and commercial strategy are no longer separate conversations.

For German life sciences companies, investors, and associations, the time to assess the issue is now.

When Drug Pricing Becomes a Trade Dispute

The United States has launched a Section 301 investigation into Germany over pharmaceutical pricing and reimbursement policies, with USTR characterizing the issue as “persistent underpayment for innovative pharmaceutical products.”

For multinational pharmaceutical and biotech companies operating across the Atlantic corridor, this is an important regulatory and market access signal.

The investigation appears tied to German healthcare cost-containment legislation that could further reduce spending on innovative medicines. While the trade process may take time to unfold, the larger issue is already clear: domestic healthcare pricing policy is now being viewed through a trade enforcement lens.

That matters because Germany is not just another European market. It is one of the most important pharmaceutical markets in Europe, and its reimbursement policies can influence launch sequencing, pricing strategy, and broader European market planning.

For life sciences companies, this creates a new layer of uncertainty. Pricing, reimbursement, intellectual property protection, market access, and trade enforcement are no longer separate conversations. They are becoming part of the same commercial risk analysis.

The investigation also reflects a broader U.S. policy argument: American patients and companies should not carry a disproportionate share of the global cost of pharmaceutical research and development while other wealthy markets use aggressive reimbursement controls to limit spending.

This does not mean tariffs are inevitable. USTR has suggested that the issue could potentially be resolved through negotiations, including a path that expands access to innovative medicines while ensuring fair reimbursement for pharmaceuticals made by American workers. Still, the use of Section 301 against Germany is significant because it shows how quickly pricing policy can become a trade dispute.

For pharmaceutical and biotech companies, the takeaway is clear. Market-entry strategy cannot focus only on regulatory approval or clinical value. It also has to account for how governments use pricing rules, budget controls, and trade tools to shape the value of innovation.

This is exactly the type of geopolitical and market access risk we track closely at Lanton Strategies International. As pricing policy and international trade enforcement continue to intersect, companies will need to think more carefully about where they launch, how they price, and how policy risk affects long-term commercial planning.